with IBD is associated with higher rates of hospitalization, surgery, longer hospital stays, increased health care charges, and, most importantly, increased mortality. 9, 10 Much of what is known about CDI in IBD has been derived from large national databases and administrative health care data. These data have provided information about increased risks of mortality and colectomy in IBD patients with CDI and how these risks have increased over time. 10, 11 However, many of the findings were derived from retrospective samples and administrative data and are unable to account for a patient's inherent risk of CDI or their disease severity before infection. 12 We are unaware of any study that has used a propensity score matching approach to generate a control cohort that has similar risk factors for developing CDI in the year before infection. Our primary aim was to determine the impact of CDI on biomarkers of IBD severity, health care utilization, and patientreported outcomes compared with a matched cohort based on known risk factors for infection. Our secondary aim was to investigate if changes of health care utilization patterns continued into the year after infection. We hypothesized that CDI would negatively impact patient outcomes in the acute period of infection and in the long-term follow-up period.
MATERIALS AND METHODS AND DESIGN Study Design and Participants
This study was conducted as a part of the UPMC IBD research registry, which has been previously described in detail. 13 Briefly, patients with IBD are consented and enrolled in a prospective, longitudinal, natural history registry, which organizes real-world patient care data from 2009 to the present time. All data from the registry are derived from the electronic medical record and systematically processed and transformed for research.
In this study, we included all patients with IBD in the UPMC IBD registry with a definite diagnosis based on the standard criteria of ulcerative colitis (UC) or Crohn's disease (CD) for our selection of cases and controls. CDI was defined as any patient with a confirmed molecular laboratory diagnosis of C. difficile from 2010 to 2014 calendar years. All confirmed molecular diagnoses were assumed to have infection. Participants with CDI also had to have clinical follow-up, defined as at least 1 clinic visit or telephone encounter in the gastroenterology clinic over the calendar year, in the year before infection to meet inclusion criteria. Controls were selected from the remaining IBD registry participants without a history of CDI.
Patients with IBD in both the case and control groups were excluded if they had unclassified IBD or undefined disease type. To allow capture of data from the year before and year after CDI, IBD patients with CDI occurring in 2009 or 2015 were excluded. CDI cases were also excluded if they did not have the clinical follow-up in the year before infection. We did not exclude controls who had been tested for infection, or CDI-positive participants who had multiple or relapsing infections, as this is a feature of CDI in patients with IBD. 14 The CDI-positive cohort includes IBD patients with single and multiple positive tests for CDI documented in the medical record.
Data Collection and Organization
All data are prospectively collected as a part of routine health care visits in any UPMC affiliated hospital or clinic (comprising over 20 hospitals and 500 clinics). 13 All IBDrelated health care utilization including clinic visits, telephone encounters, hospitalizations, emergency department (ED) visits, and IBD-related surgeries were derived from the IBD registry and temporally organized by calendar year. Health care utilization was also quantified by financial charges, which includes charge data for all health care services including, but not limited to, gastrointestinal care. Financial charges include both inpatient and outpatient charges, but do not include pharmacy charges as prescription charges independent of the UPMC system. Laboratories were ordered as a part of routine care as deemed appropriate by providers; therefore, laboratory biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and vitamin D and B-12 deficiencies were organized by calendar year and dichotomized as normal or abnormal based on local laboratory standards. All outpatient electronic prescriptions were organized annually for each patient. Patients were designated as having exposure to the medication if they had one or more prescriptions within the calendar year. Antibiotics only included systemic exposure. Systemic antibiotics with the exception of vancomycin and fidaxomicin were analyzed as a separate category. Within the systemic antibiotics category, we looked at the subgroup of patients prescribed metronidazole, as it is indicated in the setting of CDI. However, vancomycin and fidaxomicin were analyzed alone as a separate antibiotic category, as their primary indications are for CDI.
Patient-reported disease activity and quality-of-life (QOL) metrics were collected during clinical visits to the UPMC Digestive Disorders Clinic as a part of routine care, and entered into the electronic medical record. QOL was measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). 15 Disease activity was measured by the Harvey-Bradshaw Index (HBI) for CD and Ulcerative Colitis Activity Index (UCAI) for UC. 16, 17 "Active disease" was defined as an annual mean UCAI score of $4 or annual mean HBI scores of $5 during the study period. Disease phenotypic characterization was performed in both patients with CD and UC using the Montreal classification at initial presentation. 18 
Propensity Score Matching
To build a comparable control cohort at baseline, we used nearest neighbor propensity score matching. 19 We generated the propensity score for CDI with the covariates listed in Supplementary Table 1 , Supplemental Digital Content 1, http://links. lww.com/IBD/B631 using logistic regression. The propensity score is considered the calculated "likelihood" of infection, given a patient's particular set of covariates. 20 All covariates were chosen from hypothesis-driven clinical parameters that may influence a patient's risk for CDI. Most importantly, we included all encounters with the health care system and antibiotic exposures in the year before infection, which have been implicated in risk of infection. 2, 3 We also included all antibiotic exposures in the year before infection, age, and vitamin D deficiency, all which have been linked to risk of infection. 5, 7 Patients were matched using the protocol outlined in Figure 1 , which features a rolling propensity score matching process over time beginning with study participants who had their first CDI event in 2010. Matching was performed without replacement to build a 1:2 (cases:controls) cohort. Any control matched to a case in previous years was excluded from any subsequent control population selection pool. Covariate balance in the year before infection was examined after matching.
Statistical Analysis
We used chi-square analyses for categorical variables, Student's t test for normally distributed continuous variables, and the Wilcoxon rank-sum test for nonparametric continuous variables to assess differences and balance between groups at baseline. To account for matching, outcomes in the year of infection and the year after infection were assessed using conditional logistic regression for binary outcomes, and fixed effects regression for continuous variables. Counts of health care utilization (hospitalizations, ED visits, telephone calls, clinic visits, radiologic procedures, and endoscopies) were initially evaluated using fixed effects Poisson regression, and significance was ultimately reported using conditional negative binomial regression due to over dispersion of zeros. Financial charges were transformed to natural log for normality before regression. All statistical tests were evaluated with an alpha ¼ 0.05 and were completed in StataSE (v.14; StataCorp, College Station, TX).
Ethical Considerations
All participants were enrolled in the IBD Research Registry using informed consent. The IBD Research Registry (Protocol #0309054) and the current analysis (Protocol #15010214) were both approved by the University of Pittsburgh Institutional Review Board. All authors had access to the study data and reviewed and approved the final manuscript.
RESULTS
A total of 198 patients (66 CDI and 132 matched controls) were included (56.6% women; 60.1% CD, 39.9% UC) ( Table 1) . Infection and control groups did not significantly differ in terms of baseline disease characteristics in the year before infection for all available metrics ( Table 2 ). Study groups did not differ in regard to contact with the health care system including hospitalizations, ED visits, endoscopies, radiologic studies, clinic visits, and total financial charges. In addition, the groups did not differ in terms of the proportion of patients who were exposed to antibiotics or the number of times they were prescribed antibiotics ( Table 2) .
Year of Infection
In the year of CDI, follow-up occurred in 93.4% (n ¼ 185) of the cohort, and rates of follow-up did not differ between infection and control groups (95.5% CDI versus 92.4% controls). Having CDI was significantly associated with increased medication exposure including steroids (49.2% CDI versus 28.7% controls, P ¼ 0.005), systemic antibiotics (excluding vancomycin) (90.5% CDI versus 50.8% controls, P , 0.001), and vancomycin exposure (73.0% CDI versus 12.3% controls, P , 0.001) ( Table 3) . Neither group had any exposure to fidaxomicin or fecal microbiota transplantation. The CDI group also had a greater total number of antibiotic prescriptions (median: 3 CDI cases versus 1 control, P , 0.001). The 2 groups did not differ in their exposure to 5-aminosalicylic acid, immunomodulators, or biological medications (Table 3) .
Infection was also significantly associated with elevated inflammatory biomarkers, including CRP (58.7% CDI versus 32.0% controls, P ¼ 0.002) and ESR (41.3% CDI versus 18.0% controls, P ¼ 0.002), low vitamin D (P ¼ 0.001), and low vitamin B-12 (P ¼ 0.02) ( Table 3 ). Using patient-reported metrics, infection was associated with lower QOL scores (P ¼ 0.003) and selfreported active disease (P ¼ 0.02) ( Table 3) .
Patients with CDI experienced significantly increased health care utilization across all measured metrics except the proportion of patients requiring surgery during the year of infection (Table 3 ). Those with CDI had an increased number of radiographic studies, endoscopies, clinic visits, and telephone encounters (all P , 0.001). They also had more unplanned care, including ED visits (mean: 3.7 CDI versus 1.1 controls, P , 0.001) and hospitalization (mean: 2.2 CDI versus 0.8 controls, P , 0.001). Patients with CDI had increased financial health care charges in the year of infection (P , 0.001) ( Table 3 ). 
Year After Infection
In the year after infection, follow-up occurred in 77.8% (n ¼ 154) of the original study group. The CDI group includes patients with single or multiple positive tests for CDI. Patients with CDI were significantly more likely to follow-up in the year after infection (CDI 90.9%; controls 71.2%) compared with controls (P ¼ 0.003), (Table 4) .
Those with previous CDI continued to have increased exposure to vancomycin (P , 0.001) and other systemic antibiotics (P ¼ 0.02). Neither group had any exposure to fidaxomicin or fecal microbiota transplantation in the year after infection. All other medication exposures, including biologics, systemic steroids, immunomodulators, and 5-aminosalicylic acid agents, did not differ between groups, although exposure to systemic steroids nearly met significance (P ¼ 0.07) ( Table 4) . In the year after infection, patients with CDI continued to have more clinic visits (P ¼ 0.02) and telephone encounters (P ¼ 0.001). Patients with CDI also had significantly more financial health care charges in the year after infection (median $51,146.00 CDI versus $8120.50 controls, P ¼ 0.003). However, patient-reported disease activity, QOL (P ¼ 0.08), and biomarkers of severity, including ESR and CRP, were not significantly different between the 2 groups. Other metrics of health care utilization, including radiologic studies, endoscopy, surgery, hospitalizations, and ED visits, were not significantly different (Table 4) .
Year After Infection, Excluding Patients with Multiple Infections
Of the 60 patients with CDI who had follow-up in the year after infection, there were 18 patients (30%) who had more than 1 CDI documented with molecular testing during their participation in the UPMC IBD research registry. We performed a subgroup analysis of the patients who followed up the year after infection and did not have multiple documented infections (n ¼ 136: 42 CDI cases and 94 controls). When patients who had more than 1 documented CDI were excluded, we observed that higher exposure to vancomycin in the CDI group remained significant (33.3% CDI versus 11.7% controls, P ¼ 0.03) in the year after infection. Meanwhile, the exposure to all other classes of antibiotics was no longer significantly different (P ¼ 0.64) between the 2 groups.
After 
DISCUSSION
In this propensity score matched analysis of patients with CDI compared with controls, participants were matched on risk factors for C. difficile in the year before infection. Although groups did not differ at in any measured metrics at baseline, those who developed CDI in the following year demonstrated significantly increased biomarkers of inflammation (CRP and ESR), increased patient-reported metrics of disease severity, increased medication exposure, decreased QOL, and significantly increased inpatient and outpatient health care utilization compared with controls. Interestingly, the increase in health care utilization and antibiotic exposure extended into the year after infection for patients with CDI. Differences in QOL just failed to reach statistical significance in the year after infection. This could be due to the statistically lower follow-up in the control group in the year after infection. The poor follow-up in the control group results in fewer QOL scores completed from patients who are likely feeling well. Overall, the findings suggest that CDI has a lasting and measureable impact on patients with IBD beyond the acute care period.
Previous research has shown that CDI in IBD is associated with systemic inflammation and disease activity, which we validated in this propensity matched cohort study. 21, 22 In addition to association with measures of disease severity, we observed that patients with CDI were more frequently prescribed and exposed to systemic steroids during the year of infection. This could be due to worsening of symptoms initially believed to be a flare of IBD and may have been attributable to infection, or CDI that precipitates an IBD flare. These data highlight the difficulty of diagnosis and importance of proper management of CDI in the setting of IBD, as both infection and disease flare present with similar symptoms of elevated inflammatory biomarkers and diarrhea.
A recent meta-analysis demonstrated that CDI is a significant risk factor for colectomy in patients with IBD. 11 Our study failed to find differences in the proportion of patients requiring surgery in the year of infection and the year after. This could be due to the baseline matching, which selected for a severe disease cohort from the outset, placing both groups at higher risk of surgery than the general IBD population. This is supported by the fact that a third of patients had a history of IBD-related surgery before study enrollment, and approximately 15% of patients had surgery in the year before infection. In the year of infection, approximately 9% of patients had an IBD-related surgery, and this was similar between groups. Other reasons for the lack of surgical endpoints in this study includes the relatively small cohort of patients, and that we did not exclude patients who had previous surgery or colectomy.
In this study, we included participants who had multiple positive molecular tests for CDI. Recurrent infection is a significant and important feature of CDI in the setting of IBD that we hoped to characterize with longitudinal observational data. In addition, many patients with IBD are treated empirically without repeat molecular testing because of the high likelihood that persistent symptoms represent CDI recurrence in the setting of IBD. Similar to other studies, we observed that approximately one-third of patients experience repeat infection confirmed with molecular testing. 14 To ensure that patients with documented recurrent infection were not influencing the results of the statistically significant parameters, we repeated the analysis excluding this fraction of patients and found similar significant results in relation to increased vancomycin antibiotic exposure, increased telephone encounters possibly due to continuing empiric therapy, and increased financial charges, which serves as an all-encompassing health care utilization metric. However, the differences in the number of clinic visits were no longer statistically significant.
This study was performed at a tertiary care center, and therefore may not be generalizable to patients in the community setting. However, the UPMC IBD registry collects all data from the electronic medical record, which includes over 22 different hospitals and 500 clinics in the surrounding community. This analysis is only restricted to those patients who are enrolled in the UPMC IBD research registry, and is therefore subject to participation bias. Given the strict inclusion criteria of requiring clinical follow-up in the year before infection, we may have missed valuable data on patients initially presenting to our tertiary care clinic for worsening disease that could be attributed to CDI, or were diagnosed with CDI on their first visit to the Digestive Disorders Center. We recognize that there is a testing bias, as only those initially tested for CDI due to clinical suspicion were included in our CDI cohort. Choice of methodology for testing was not standardized among providers and not captured in the registry data; therefore, we do not have detailed data regarding colonization as compared to infection. The size of our cohort is also relatively small, including only 66 patients with CDI; therefore, some of our measured outcomes in the year after infection may have lacked statistical power because of low sample size. Despite the small size of our study cohort, we were able to observe highly significant differences between the matched groups in the year of infection and the year after infection. This is the first propensity score matched analysis of a CDI cohort in the setting of IBD. This approach helps to alleviate many of the caveats associated with a random sample, as those who have a history of infection may be inherently different because of risk factors associated with infection. These data are prospectively derived from the electronic medical record and represent real-world care of patients with IBD, as it is not collected under the standardized setting of a clinical trial. The analysis of real-world data brings us closer to understanding typical care patterns and the true IBD patient experience of CDI.
In conclusion, CDI negatively impacts the clinical course of IBD in the year of infection and also has lasting and measurable effects. CDI results in increased IBD activity, elevated biomarkers of inflammation, poor health-related QOL, and increased health care utilization during the year of infection, some of which extends into the year after infection. Given the dramatic impact of CDI on IBD, future studies evaluating treatment strategies of CDI in IBD are needed. 
